Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of HPK1 kinase inhibitors for prevention and/or treatment of pathogen infections in animals

A kinase inhibitor and pathogen infection technology, applied in the field of chemical medicine, can solve the problems of virus mutation, high morbidity and mortality of viral diseases, and high cost.

Pending Publication Date: 2021-12-17
ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although with the continuous development of medical technology, many vaccines related to viral diseases have been developed, but the virus may mutate, and the effectiveness of the vaccine against emerging viruses needs to be evaluated, and the cost is large. The morbidity and mortality of viral diseases It is still high, so the veterinary field has a great demand for drugs with good antiviral effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of HPK1 kinase inhibitors for prevention and/or treatment of pathogen infections in animals
  • Use of HPK1 kinase inhibitors for prevention and/or treatment of pathogen infections in animals
  • Use of HPK1 kinase inhibitors for prevention and/or treatment of pathogen infections in animals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] 1. Experimental method

[0131] 8-month-old British shorthair cat (Lele), female intact, weighing 2.5kg. In January 2020, the cat developed symptoms such as elevated body temperature, depression, loss of appetite, and enlarged abdominal circumference. One week later, he was admitted to the hospital for consultation. On January 18, he was diagnosed as positive for feline infectious peritonitis (FIP). After 3 days of treatment with GS-441524, he continued to use furosemide, surox, prednisolone, and itraconazole (oral, q 24h, 10mg / kg) for 1 month, the drug was discontinued after the disappearance of ascites. At the beginning of April, the condition recurred, the appetite decreased, and the spirit was listless. X-ray detection showed pleural effusion, and PCR detection was positive for feline coronavirus (CT value 25.11). Enrolled on April 8, day 1-14 (D1-14): Administer the drug of the present invention at 2.0 mg / kg, SC q 24h. At the same time, give appropriate supporti...

Embodiment 2

[0149] A total of 15 cats with FIP were enrolled in the clinical diagnosis group, with pleural / ascites, positive CT value of PCR test, and no neurological symptoms. Among them, 8 cats were in the control group and 7 were in the experimental group.

[0150] Each group first used GS-441524 for 3 days, then D1-D14 of the control group: give necessary supportive treatment, D1-D14 after 3 days of observation in group A: give necessary supportive treatment, and give the drug of the present invention 2.0mg / kg , SC q 24h.

[0151] If death or neurological symptoms occur, it is judged as clinical death, and the clinical survival curve is calculated after 14 days. The results are as follows: figure 2 shown. The Log Rank (Mantel-Cox) and Breslow (Generalized Wilcoxon) methods were used to test the validity, and the results of the two methods were significantly different (P<0.05).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an HPK1 kinase inhibitor in preventing and / or treating pathogen infection of animals. The HPK1 kinase inhibitor is a small-molecule HPK1 kinase inhibitor, in particular a compound shown in a general formula I or pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate or deuterated compound thereof. The HPK1 kinase inhibitor can be used for effectively treating diseases (such as feline infectious peritonitis) caused by animal pathogen (especially virus such as coronavirus) infection and improving the survival condition of animals, and has better commercial value and application prospect in the field of veterinary antiviral (especially virus such as coronavirus) medicines.

Description

technical field [0001] The invention relates to the technical field of chemical medicine, in particular to the application of an HPK1 kinase inhibitor in the prevention and / or treatment of animal pathogen (especially virus, such as coronavirus) infection. Background technique [0002] Viral diseases are one of the most serious diseases to animals in veterinary clinics, especially the prevalence of some highly pathogenic viral diseases, which often bring huge economic and spiritual losses to the owners. Animal viral diseases usually spread quickly, with high morbidity and fatality rates, which seriously endanger the health and life of animals. Moreover, some viruses can also be transmitted to humans through animals, posing a threat to human life. [0003] Viral diseases in animals can be caused by a wide variety of viruses, for example, Herpesviridae, Rhabdoviridae, Reoviridae, Poxviridae, African Swine Fever Viridae, Adenoviridae, Parvoviridae, Circoviruses Viridae, Orthom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4545A61K31/496A61K31/444A61K31/497A61K31/4439A61K31/551A61K31/501A61K31/506A61P31/14A61P11/00A61P1/00A61P1/12A61P17/00A61P35/02A61P7/06A61P31/16A61P43/00
CPCA61K31/4545A61K31/496A61K31/444A61K31/497A61K31/4439A61K31/551A61K31/501A61K31/506A61P31/14A61P11/00A61P1/00A61P1/12A61P17/00A61P35/02A61P7/06A61P31/16A61P43/00A61P31/20A61P31/22A61K31/5377C07D417/14A61P31/12C07D401/14C07D417/04C07D421/14C07D405/14A61P29/00
Inventor 林星雨陆婷婷
Owner ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com